The effects of fasudil on the permeability of the rat blood–brain barrier and blood–spinal cord barrier following experimental autoimmune encephalomyelitis-Reference-Cited by-同舟云学术

The effects of fasudil on the permeability of the rat blood–brain barrier and blood–spinal cord barrier following experimental autoimmune encephalomyelitis

Published:2011-10 Issue:1-2 Volume:239 Page:61-67
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Huang X.N.,Fu J.,Wang W.Z.

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,Immunology,Immunology and Allergy

Reference55 articles.

1. Immunopathogenesis of multiple sclerosis;Agrawal;Int. Rev. Neurobiol.,2007

2. Ninjurin1 is expressed in myeloid cells and mediates endothelium adhesion in the brains of EAE rats;Ahn;Biochem. Biophys. Res. Commun.,2009

3. Disruption of central nervous system barriers in multiple sclerosis;Alvarez;Biochim. Biophys. Acta,2010

4. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase;Amano;Science,1997

5. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein;Balda;J. Cell Biol.,1996

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of the ROCK inhibitor fasudil on the brain proteomic profile in the tau transgenic mouse model of Alzheimer's disease;Frontiers in Aging Neuroscience;2024-02-19

2. Transcriptome analysis of fasudil treatment in the APPswe/PSEN1dE9 transgenic (APP/PS1) mice model of Alzheimer’s disease;Scientific Reports;2022-04-22

3. NMDA mediates disruption of blood-brain barrier permeability via Rho/ROCK signaling pathway;Neurochemistry International;2022-03

4. Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases;Neural Regeneration Research;2022

5. ROCKs as a potential drug target to combat Alzheimer's disease;Protein Kinase Inhibitors;2022